REFERENCES:
  1. Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer . 1972; 29:1705-1712.
  2. Jennings WC, Baker RS, Murray SS, Howard CA, Parker DE, Peabody LF et al. Primary breast lymphoma. The role of mastectomy and the importance of lymph node status. Ann Surg 2007; 245:784-789.
  3. Peng F, Li J, Mu S, Cai L, Fan F, Qin Y, Ai L, Hu Y. Epidemiological features of primary breast lymphoma patients and development of a nomogram to predict survival. Breast 2021 Jun; 57:49-61.
  4. Kim SH, Ezekiel MP, Kim RY. Primary lymphoma of the breast. Am J Clin Oncol. 1999; 22:381-383.
  5. Shapiro CM, Mansur D. Bilateral primary breast lymphoma. Am J Clini Oncol. 2002; 24:85-86
  6. Wong WW, Schild SE, Halyard MY, Schomberg PJ. Primary non-Hodgkin’s lymphoma of the Mayo Clinic Experience. J Surgical Oncol . 2002; 80(1): 19-25, discussion 26.
  7. Jeon HJ, Akagi T, Hoshida Y, Hayashi K, Yoshino T, Tanaka T et al.  Primary non-
  8. Hodgkin lymphoma of the breast. An immunohistochemical study of seven patients and literature review of 152 patients with breast lymphoma in Japan. Cancer  1992; 70:2451–2459.
  9. Sabate, JM, Gomez A, Torruba S, Camins A, Roson N, De Las Heras P. Lymphoma of the breast: clinical and radiological features with pathologic correlation in 28 patients. Breast J.  2002; 8:294–304. Domchek SM, Hecht JL, Fleming MD, Pinkus GS, Canellos GP. Lymphomas of the breast. Cancer  2002; 94:6–13.
  10. Schouten JT, Weese JL, Carbone PP. Lymphoma of the breast. An Surg.  1981; 194:749–753.
  11. Ganjoo K,Advani R, Mariappan MR, McMillian A, Horning S. Non-Hodgkin lymphoma of the breast. Cancer 2007; 110:25-30.
  12. Lyou CY, Yang SK, Choe DH, Lee BH, Kim KH. Mammographic and sonographic findings of primary breast lymphoma. Clin Imaging  2007; 31:234–238.
  13. Cheah CY, Campbell BA, Seymour JF. Primary breast lymphoma.Cancer Treat Rev 2014; 40:900-908
  14. Jain MF, Khandekar SL, Mahadani JW, et al. Report of a case of primary breast lymphoma highlighting the importance of fine needle aspiration cytology as initial diagnostic tool. J. Cytol. 2015; 32: 127.
  15. Chen M, Zhou J, Qu X. Primary breast diffuse large B-cell lymphoma in a 42-year-old female: a case report and review of literature. J Med Cases 2021; 12:181–5.
  16. Ryan G, Martinelli G Kuper-Hommel M, et al; International Extranodal Lymphoma Study Group. Primary diffuse large B-cell lymphoma of the breast; prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol. 2008; 19(2):233-241.
  17. Yhim HY, KimJS, Kang HJ, Kim WS, Choid CW, et al, Matched-pair analysis comparing the outcomes of primary breast and nodal diffuse large B-cell lymphoma in patients treated with rituximab plus chemotherapy. Int J Cancer 2012; 131:235-243
  18. Hosein PJ, Maragulia JC, Salzberg MP, Press OW, Habermann TM, Vose JM, et al. A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era. BR J Haematol 201; 165:358-363.
  19. Jeanneret-Sozzi W, Taghian A, Epelbaum R, Poortmans P, Zwahlen D, Amsler B, et al. Primary breast lymphoma: patient profile, outcome and prognostic factors. A multicentre Rare Cancer Network Study. BMC Cancer 2008; 8:1471-2407.
  20. Aviles A, Neri N, Nambo. The role of genotype in 104 cases of diffuse large B-cell lymphoma primary of breast. Am J Clin Oncol . 35 (2) 2012;126-129.
  21. Adapted with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Diffuse Large B-Cell Lymphoma V.5.2023. © 2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to NCCN.org. The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.
  22. Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index; a risk model for CNS relapse in patient with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016; 34(26): 3150-3156.
  23. Schmitz N, Frontzek F. CNS prophylaxis in DLBCL: time to say goodbye?Blood. 2022 Jan 20; 139 (3): 315-317.
  24. Orellana-Noia VM, Reed DR, McCook AA, Sen JM, Barlow CM, Malecek MK, et al. Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions.Blood. 2022 Jan 20; 139(3) 413-423.
  25. Aviva A, Tadmor T, Polliack A. Primary diffuse large B-cell lymphoma of the breast: looking at pathogenesis, clinical issues and therapeutic options. Annals of Oncology . Volume 24, Issue 9, 2013: 2236-2244,
  26. Zhang W, Huang C, Liu J, Wu L, Zhang H, Wu X, Wang L, Li W, Liu W, Liu L. Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis. Dis Markers . 2022 Jul 29; 2022:6441139.